Plasma testosterone and arrhythmic events in male patients with arrhythmogenic right ventricular cardiomyopathy
ConclusionsThe levels of plasma testosterone in ARVC male patients are higher than those in healthy males. Testosterone level, without relation to the baseline cardiac function and future significant structural progression events, is a strong predictor of future adverse arrhythmic events in male patients with ARVC. Therefore, our results suggest that testosterone may be a useful biomarker in arrhythmic risk prediction in the ARVC.
Source: ESC Heart Failure - Category: Cardiology Authors: Jie Ren,
Liang Chen,
Ningning Zhang,
Xiao Chen,
Qian Zhao,
Kai Chen,
Xiangjie Li,
Frank Ruschitzka,
Firat Duru,
Jiangping Song Tags: Original Research Article Source Type: research
More News: Arrhythmia | Cancer & Oncology | Cardiology | Cardiomyopathy | China Health | Heart | Heart Failure | Hormones | Study | Ventricular Arrhythmia